Share Price and Basic Stock Data
Last Updated: October 18, 2025, 6:03 pm
| PEG Ratio | 0.15 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Natco Pharma Ltd has demonstrated a robust revenue trajectory, with reported sales standing at ₹2,707 Cr for FY 2023, a significant increase from ₹1,945 Cr in FY 2022. The company recorded a remarkable growth in sales, reaching ₹4,430 Cr in FY 2025, indicating a consistent upward trend. Quarterly sales figures further illustrate this momentum, with ₹1,140 Cr reported in Jun 2023, rising to ₹1,363 Cr by Jun 2024. Conversely, expenses also escalated, recorded at ₹1,772 Cr in FY 2023, which slightly declined to ₹2,234 Cr in FY 2025. The operating profit margin (OPM) exhibited variability, peaking at 59% in Jun 2024, reflecting strong operational efficiency. This consistent revenue growth can be attributed to Natco’s strategic focus on product innovation and market expansion, particularly in the oncology segment. However, fluctuations in quarterly performance, such as a dip to ₹475 Cr in Dec 2024, highlight the potential seasonality in their revenue streams.
Profitability and Efficiency Metrics
Natco Pharma’s profitability metrics underscore its operational effectiveness, with a recorded net profit of ₹1,883 Cr for FY 2025, up from ₹715 Cr in FY 2023. The earnings per share (EPS) rose significantly to ₹105.26 in FY 2025, reflecting the company’s ability to enhance shareholder value. The return on equity (ROE) stood at an impressive 28%, while return on capital employed (ROCE) reached 32.8%, indicating efficient capital utilization. The interest coverage ratio (ICR) was notably strong at 106.72x, showcasing the company’s capacity to service its debt comfortably. However, the cash conversion cycle (CCC) of 362 days suggests that Natco may face challenges in converting its investments into cash, which could impact liquidity. Although the company has maintained a healthy net profit margin of 42.51% for FY 2025, the fluctuations in OPM, particularly a low of 8% in Dec 2024, warrant attention to operational stability.
Balance Sheet Strength and Financial Ratios
Natco Pharma’s balance sheet reflects financial prudence, with total assets reported at ₹8,631 Cr and total liabilities at ₹8,631 Cr as of FY 2025. The company has maintained a low debt-to-equity ratio of 0.03, indicating minimal reliance on external financing. Reserves have substantially increased to ₹7,571 Cr, reinforcing the company’s financial stability and capacity for future growth. The current ratio of 5.59x and quick ratio of 4.77x highlight strong liquidity, suggesting that Natco can meet its short-term obligations comfortably. However, the inventory turnover ratio of 0.73x indicates potential inefficiencies in inventory management, which could tie up capital. Additionally, as Natco navigates its growth trajectory, the interest coverage ratio and low borrowing levels position it favorably against competitors in the pharmaceuticals sector, where higher debt levels are common.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Natco Pharma reflects a stable investor base, with promoters holding 49.56% as of Mar 2025. Foreign institutional investors (FIIs) accounted for 15.52%, while domestic institutional investors (DIIs) held 5.81%, indicating a balanced mix of institutional and retail investor participation. The public shareholding rose to 29.12%, reflecting growing confidence among individual investors. The number of shareholders increased significantly to 4,29,434, up from 1,21,336 in Sep 2022, suggesting heightened interest in the company’s performance. Despite fluctuations in FII holdings, the overall trend indicates a robust interest from the market. However, the gradual decline in FII holdings from 17.49% in Mar 2025 to 15.52% in Jun 2025 may raise concerns about foreign investor sentiment, which could impact stock performance in the near term.
Outlook, Risks, and Final Insight
If margins sustain their upward trajectory and the company continues to enhance its product pipeline, Natco Pharma is well-positioned for long-term growth. However, the variability in quarterly performance and the extended cash conversion cycle present potential risks that management must address. Additionally, the pharmaceutical industry faces regulatory challenges and pricing pressures, which could impact profitability. Maintaining operational efficiency and managing inventory effectively will be crucial for Natco to leverage its financial strengths. If the company can navigate these challenges while capitalizing on its robust market position, it may continue to deliver strong returns to its shareholders. The focus on innovation and strategic partnerships will be key drivers for sustaining growth in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Natco Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 885 | 432 | 492 | 898 | 1,140 | 1,031 | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 |
| Expenses | 489 | 337 | 387 | 559 | 612 | 573 | 490 | 571 | 558 | 567 | 436 | 673 | 758 |
| Operating Profit | 395 | 95 | 106 | 339 | 528 | 458 | 268 | 497 | 805 | 804 | 39 | 548 | 571 |
| OPM % | 45% | 22% | 22% | 38% | 46% | 44% | 35% | 47% | 59% | 59% | 8% | 45% | 43% |
| Other Income | 34 | 20 | 21 | 29 | 20 | 29 | 37 | 42 | 48 | 64 | 176 | 66 | 62 |
| Interest | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 10 | 3 |
| Depreciation | 40 | 42 | 42 | 41 | 44 | 44 | 44 | 56 | 44 | 46 | 47 | 98 | 58 |
| Profit before tax | 386 | 70 | 81 | 324 | 500 | 440 | 256 | 478 | 804 | 818 | 164 | 506 | 572 |
| Tax % | 17% | 19% | 23% | 15% | 16% | 16% | 17% | 19% | 17% | 17% | 19% | 20% | 16% |
| Net Profit | 320 | 57 | 62 | 276 | 420 | 369 | 213 | 386 | 668 | 676 | 132 | 406 | 480 |
| EPS in Rs | 17.55 | 3.11 | 3.41 | 15.11 | 23.47 | 20.60 | 11.88 | 21.57 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 |
Last Updated: August 20, 2025, 6:25 am
Below is a detailed analysis of the quarterly data for Natco Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,329.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,221.00 Cr. (Mar 2025) to 1,329.00 Cr., marking an increase of 108.00 Cr..
- For Expenses, as of Jun 2025, the value is 758.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 673.00 Cr. (Mar 2025) to 758.00 Cr., marking an increase of 85.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 571.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 571.00 Cr., marking an increase of 23.00 Cr..
- For OPM %, as of Jun 2025, the value is 43.00%. The value appears to be declining and may need further review. It has decreased from 45.00% (Mar 2025) to 43.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 7.00 Cr..
- For Depreciation, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 98.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 40.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 572.00 Cr.. The value appears strong and on an upward trend. It has increased from 506.00 Cr. (Mar 2025) to 572.00 Cr., marking an increase of 66.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Mar 2025) to 16.00%, marking a decrease of 4.00%.
- For Net Profit, as of Jun 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 406.00 Cr. (Mar 2025) to 480.00 Cr., marking an increase of 74.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 26.84. The value appears strong and on an upward trend. It has increased from 22.70 (Mar 2025) to 26.84, marking an increase of 4.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: September 10, 2025, 5:37 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 739 | 825 | 1,042 | 2,020 | 2,185 | 2,094 | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 | 4,430 | 4,396 |
| Expenses | 560 | 615 | 777 | 1,337 | 1,256 | 1,300 | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 | 2,234 | 2,434 |
| Operating Profit | 179 | 210 | 266 | 683 | 928 | 795 | 583 | 606 | 264 | 936 | 1,754 | 2,196 | 1,962 |
| OPM % | 24% | 25% | 25% | 34% | 42% | 38% | 30% | 30% | 14% | 35% | 44% | 50% | 45% |
| Other Income | 17 | 0 | 12 | 14 | 40 | 130 | 107 | 104 | 99 | 105 | 126 | 354 | 368 |
| Interest | 37 | 32 | 23 | 18 | 15 | 19 | 22 | 13 | 18 | 14 | 19 | 24 | 22 |
| Depreciation | 30 | 47 | 51 | 54 | 66 | 81 | 100 | 117 | 143 | 164 | 187 | 235 | 249 |
| Profit before tax | 129 | 132 | 204 | 624 | 887 | 825 | 569 | 580 | 202 | 862 | 1,674 | 2,291 | 2,060 |
| Tax % | 24% | 1% | 24% | 22% | 22% | 22% | 19% | 24% | 16% | 17% | 17% | 18% | |
| Net Profit | 98 | 130 | 156 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,695 |
| EPS in Rs | 6.21 | 8.10 | 9.02 | 27.88 | 37.74 | 35.24 | 25.31 | 24.18 | 9.31 | 39.18 | 77.51 | 105.26 | 94.78 |
| Dividend Payout % | 16% | 12% | 14% | 24% | 22% | 18% | 27% | 22% | 48% | 14% | 12% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.65% | 20.00% | 210.90% | 43.30% | -7.63% | -28.66% | -3.49% | -61.54% | 320.59% | 94.13% | 35.66% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.65% | 190.90% | -167.60% | -50.92% | -21.03% | 25.17% | -58.05% | 382.13% | -226.46% | -58.46% |
Natco Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: June 16, 2025, 11:39 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 33 | 33 | 35 | 35 | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 |
| Reserves | 693 | 813 | 1,261 | 1,614 | 3,035 | 3,452 | 3,737 | 4,085 | 4,227 | 4,837 | 5,817 | 7,571 |
| Borrowings | 240 | 312 | 113 | 222 | 173 | 386 | 316 | 268 | 416 | 167 | 371 | 279 |
| Other Liabilities | 229 | 226 | 413 | 446 | 470 | 428 | 498 | 403 | 430 | 617 | 682 | 744 |
| Total Liabilities | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 |
| Fixed Assets | 645 | 710 | 710 | 833 | 1,019 | 1,227 | 1,584 | 2,023 | 2,312 | 2,427 | 2,491 | 2,698 |
| CWIP | 124 | 129 | 212 | 336 | 480 | 638 | 518 | 223 | 130 | 64 | 137 | 225 |
| Investments | 2 | 2 | 22 | 32 | 76 | 169 | 112 | 304 | 308 | 392 | 539 | 474 |
| Other Assets | 425 | 543 | 878 | 1,116 | 2,140 | 2,270 | 2,373 | 2,242 | 2,360 | 2,774 | 3,739 | 5,234 |
| Total Assets | 1,196 | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 |
Below is a detailed analysis of the balance sheet data for Natco Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 36.00 Cr..
- For Reserves, as of Mar 2025, the value is 7,571.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,817.00 Cr. (Mar 2024) to 7,571.00 Cr., marking an increase of 1,754.00 Cr..
- For Borrowings, as of Mar 2025, the value is 279.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 371.00 Cr. (Mar 2024) to 279.00 Cr., marking a decrease of 92.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 682.00 Cr. (Mar 2024) to 744.00 Cr., marking an increase of 62.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 8,631.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,906.00 Cr. (Mar 2024) to 8,631.00 Cr., marking an increase of 1,725.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2,698.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,491.00 Cr. (Mar 2024) to 2,698.00 Cr., marking an increase of 207.00 Cr..
- For CWIP, as of Mar 2025, the value is 225.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2024) to 225.00 Cr., marking an increase of 88.00 Cr..
- For Investments, as of Mar 2025, the value is 474.00 Cr.. The value appears to be declining and may need further review. It has decreased from 539.00 Cr. (Mar 2024) to 474.00 Cr., marking a decrease of 65.00 Cr..
- For Other Assets, as of Mar 2025, the value is 5,234.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,739.00 Cr. (Mar 2024) to 5,234.00 Cr., marking an increase of 1,495.00 Cr..
- For Total Assets, as of Mar 2025, the value is 8,631.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,906.00 Cr. (Mar 2024) to 8,631.00 Cr., marking an increase of 1,725.00 Cr..
Notably, the Reserves (7,571.00 Cr.) exceed the Borrowings (279.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -61.00 | -102.00 | 153.00 | 461.00 | 755.00 | 409.00 | 267.00 | 338.00 | -152.00 | 769.00 | -370.00 | -277.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 85 | 92 | 86 | 106 | 88 | 105 | 73 | 116 | 115 | 109 | 103 |
| Inventory Days | 283 | 331 | 482 | 213 | 389 | 545 | 534 | 570 | 496 | 432 | 357 | 405 |
| Days Payable | 172 | 189 | 372 | 160 | 239 | 224 | 244 | 104 | 105 | 153 | 120 | 145 |
| Cash Conversion Cycle | 170 | 228 | 202 | 138 | 257 | 410 | 395 | 539 | 507 | 394 | 345 | 362 |
| Working Capital Days | 22 | 25 | 97 | 71 | 215 | 207 | 295 | 246 | 256 | 198 | 151 | 151 |
| ROCE % | 18% | 17% | 18% | 39% | 35% | 23% | 14% | 13% | 4% | 18% | 30% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Tata Equity P/E Fund - Regular Plan | 1,575,400 | 1.74 | 150.2 | 900,000 | 2025-09-10 00:24:41 | 75.04% |
| Tata Equity P/E Fund - Regular Plan - Trigger Option A 5% | 1,575,400 | 1.74 | 150.2 | 900,000 | 2025-09-10 00:24:41 | 75.04% |
| Sundaram Small Cap Fund | 561,369 | 1.58 | 53.52 | N/A | N/A | N/A |
| Tata Small Cap Fund | 549,064 | 0.45 | 52.35 | 900,000 | 2025-09-10 00:17:42 | -38.99% |
| Nippon India Nifty Smallcap 250 Index Fund | 113,670 | 0.44 | 10.84 | N/A | N/A | N/A |
| Nippon India Nifty Pharma ETF | 103,114 | 1.04 | 9.83 | N/A | N/A | N/A |
| Axis Nifty Smallcap 50 Index Fund | 69,721 | 1.27 | 6.65 | N/A | N/A | N/A |
| SBI Nifty Smallcap 250 Index Fund | 68,486 | 0.44 | 6.53 | N/A | N/A | N/A |
| Baroda BNP Paribas Business Cycle Fund | 58,500 | 0.96 | 5.58 | N/A | N/A | N/A |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 44,477 | 0.44 | 4.24 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 105.26 | 77.34 | 39.18 | 9.32 | 24.20 |
| Diluted EPS (Rs.) | 105.26 | 77.34 | 39.18 | 9.32 | 24.16 |
| Cash EPS (Rs.) | 118.36 | 87.99 | 48.17 | 17.13 | 30.65 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 424.97 | 326.99 | 267.06 | 233.62 | 225.94 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 424.97 | 326.99 | 267.06 | 233.62 | 225.94 |
| Revenue From Operations / Share (Rs.) | 247.46 | 223.40 | 148.33 | 106.56 | 112.44 |
| PBDIT / Share (Rs.) | 142.49 | 105.00 | 57.00 | 19.86 | 38.89 |
| PBIT / Share (Rs.) | 129.35 | 94.56 | 48.02 | 12.05 | 32.49 |
| PBT / Share (Rs.) | 128.01 | 93.49 | 47.23 | 11.08 | 31.76 |
| Net Profit / Share (Rs.) | 105.22 | 77.56 | 39.19 | 9.31 | 24.24 |
| NP After MI And SOA / Share (Rs.) | 105.33 | 77.56 | 39.19 | 9.31 | 24.16 |
| PBDIT Margin (%) | 57.57 | 47.00 | 38.42 | 18.63 | 34.58 |
| PBIT Margin (%) | 52.27 | 42.33 | 32.37 | 11.30 | 28.89 |
| PBT Margin (%) | 51.73 | 41.85 | 31.83 | 10.39 | 28.24 |
| Net Profit Margin (%) | 42.51 | 34.71 | 26.42 | 8.74 | 21.55 |
| NP After MI And SOA Margin (%) | 42.56 | 34.71 | 26.42 | 8.74 | 21.48 |
| Return on Networth / Equity (%) | 24.78 | 23.71 | 14.67 | 3.98 | 10.69 |
| Return on Capital Employeed (%) | 30.11 | 28.52 | 17.61 | 4.99 | 13.89 |
| Return On Assets (%) | 21.84 | 20.10 | 12.64 | 3.32 | 9.20 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.03 | 0.09 | 0.06 |
| Asset Turnover Ratio (%) | 0.57 | 0.63 | 0.50 | 0.36 | 0.35 |
| Current Ratio (X) | 5.59 | 4.14 | 4.39 | 3.52 | 4.45 |
| Quick Ratio (X) | 4.77 | 3.42 | 3.30 | 2.44 | 2.93 |
| Inventory Turnover Ratio (X) | 6.04 | 0.72 | 0.63 | 0.69 | 0.56 |
| Dividend Payout Ratio (NP) (%) | 5.70 | 12.25 | 14.03 | 48.29 | 25.81 |
| Dividend Payout Ratio (CP) (%) | 5.06 | 10.80 | 11.42 | 26.26 | 20.40 |
| Earning Retention Ratio (%) | 94.30 | 87.75 | 85.97 | 51.71 | 74.19 |
| Cash Earning Retention Ratio (%) | 94.94 | 89.20 | 88.58 | 73.74 | 79.60 |
| Interest Coverage Ratio (X) | 106.72 | 97.89 | 71.74 | 20.48 | 53.37 |
| Interest Coverage Ratio (Post Tax) (X) | 79.80 | 73.31 | 50.33 | 10.60 | 34.26 |
| Enterprise Value (Cr.) | 12381.23 | 16442.15 | 9905.31 | 14018.63 | 15043.09 |
| EV / Net Operating Revenue (X) | 2.80 | 4.11 | 3.66 | 7.21 | 7.33 |
| EV / EBITDA (X) | 4.85 | 8.75 | 9.52 | 38.67 | 21.19 |
| MarketCap / Net Operating Revenue (X) | 3.22 | 4.26 | 3.80 | 7.11 | 7.34 |
| Retention Ratios (%) | 94.29 | 87.74 | 85.96 | 51.70 | 74.18 |
| Price / BV (X) | 1.88 | 2.91 | 2.11 | 3.24 | 3.65 |
| Price / Net Operating Revenue (X) | 3.22 | 4.26 | 3.80 | 7.11 | 7.34 |
| EarningsYield | 0.13 | 0.08 | 0.06 | 0.01 | 0.02 |
After reviewing the key financial ratios for Natco Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 105.26. This value is within the healthy range. It has increased from 77.34 (Mar 24) to 105.26, marking an increase of 27.92.
- For Diluted EPS (Rs.), as of Mar 25, the value is 105.26. This value is within the healthy range. It has increased from 77.34 (Mar 24) to 105.26, marking an increase of 27.92.
- For Cash EPS (Rs.), as of Mar 25, the value is 118.36. This value is within the healthy range. It has increased from 87.99 (Mar 24) to 118.36, marking an increase of 30.37.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 424.97. It has increased from 326.99 (Mar 24) to 424.97, marking an increase of 97.98.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 424.97. It has increased from 326.99 (Mar 24) to 424.97, marking an increase of 97.98.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 247.46. It has increased from 223.40 (Mar 24) to 247.46, marking an increase of 24.06.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 142.49. This value is within the healthy range. It has increased from 105.00 (Mar 24) to 142.49, marking an increase of 37.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 129.35. This value is within the healthy range. It has increased from 94.56 (Mar 24) to 129.35, marking an increase of 34.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 128.01. This value is within the healthy range. It has increased from 93.49 (Mar 24) to 128.01, marking an increase of 34.52.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 105.22. This value is within the healthy range. It has increased from 77.56 (Mar 24) to 105.22, marking an increase of 27.66.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 105.33. This value is within the healthy range. It has increased from 77.56 (Mar 24) to 105.33, marking an increase of 27.77.
- For PBDIT Margin (%), as of Mar 25, the value is 57.57. This value is within the healthy range. It has increased from 47.00 (Mar 24) to 57.57, marking an increase of 10.57.
- For PBIT Margin (%), as of Mar 25, the value is 52.27. This value exceeds the healthy maximum of 20. It has increased from 42.33 (Mar 24) to 52.27, marking an increase of 9.94.
- For PBT Margin (%), as of Mar 25, the value is 51.73. This value is within the healthy range. It has increased from 41.85 (Mar 24) to 51.73, marking an increase of 9.88.
- For Net Profit Margin (%), as of Mar 25, the value is 42.51. This value exceeds the healthy maximum of 10. It has increased from 34.71 (Mar 24) to 42.51, marking an increase of 7.80.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 42.56. This value exceeds the healthy maximum of 20. It has increased from 34.71 (Mar 24) to 42.56, marking an increase of 7.85.
- For Return on Networth / Equity (%), as of Mar 25, the value is 24.78. This value is within the healthy range. It has increased from 23.71 (Mar 24) to 24.78, marking an increase of 1.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is 30.11. This value is within the healthy range. It has increased from 28.52 (Mar 24) to 30.11, marking an increase of 1.59.
- For Return On Assets (%), as of Mar 25, the value is 21.84. This value is within the healthy range. It has increased from 20.10 (Mar 24) to 21.84, marking an increase of 1.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.57. It has decreased from 0.63 (Mar 24) to 0.57, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 5.59. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.59, marking an increase of 1.45.
- For Quick Ratio (X), as of Mar 25, the value is 4.77. This value exceeds the healthy maximum of 2. It has increased from 3.42 (Mar 24) to 4.77, marking an increase of 1.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.04. This value is within the healthy range. It has increased from 0.72 (Mar 24) to 6.04, marking an increase of 5.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.70. This value is below the healthy minimum of 20. It has decreased from 12.25 (Mar 24) to 5.70, marking a decrease of 6.55.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.06. This value is below the healthy minimum of 20. It has decreased from 10.80 (Mar 24) to 5.06, marking a decrease of 5.74.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.30. This value exceeds the healthy maximum of 70. It has increased from 87.75 (Mar 24) to 94.30, marking an increase of 6.55.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.94. This value exceeds the healthy maximum of 70. It has increased from 89.20 (Mar 24) to 94.94, marking an increase of 5.74.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 106.72. This value is within the healthy range. It has increased from 97.89 (Mar 24) to 106.72, marking an increase of 8.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 79.80. This value is within the healthy range. It has increased from 73.31 (Mar 24) to 79.80, marking an increase of 6.49.
- For Enterprise Value (Cr.), as of Mar 25, the value is 12,381.23. It has decreased from 16,442.15 (Mar 24) to 12,381.23, marking a decrease of 4,060.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has decreased from 4.11 (Mar 24) to 2.80, marking a decrease of 1.31.
- For EV / EBITDA (X), as of Mar 25, the value is 4.85. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 4.85, marking a decrease of 3.90.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has decreased from 4.26 (Mar 24) to 3.22, marking a decrease of 1.04.
- For Retention Ratios (%), as of Mar 25, the value is 94.29. This value exceeds the healthy maximum of 70. It has increased from 87.74 (Mar 24) to 94.29, marking an increase of 6.55.
- For Price / BV (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.91 (Mar 24) to 1.88, marking a decrease of 1.03.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 3. It has decreased from 4.26 (Mar 24) to 3.22, marking a decrease of 1.04.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.08 (Mar 24) to 0.13, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Natco Pharma Ltd:
- Net Profit Margin: 42.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 30.11% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 24.78% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 79.8
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 8.72 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 42.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | NATCO House, Road # 2, Banjara Hills, Hyderabad Telangana 500034 | investors@natcopharma.co.in http://www.natcopharma.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. V C Nannapaneni | Chairman & Managing Director |
| Mr. Rajeev Nannapaneni | Vice Chairman & CEO |
| Mr. P S R K Prasad | Director & Exe. VP (Corp. Engg. Services) |
| Dr. D Linga Rao | Director & President (Tech. Affairs) |
| Mr. D Vijaya Bhaskar | Independent Director |
| Mr. A D M Chavali | Independent Director |
| Dr. Kantipudi Suma | Independent Director |
| Mr. Nitin Jain | Independent Director |
| Mr. Lakshminarayana Bolisetty | Independent Director |
FAQ
What is the intrinsic value of Natco Pharma Ltd?
Natco Pharma Ltd's intrinsic value (as of 19 October 2025) is 836.20 which is 1.23% higher the current market price of 826.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 14,798 Cr. market cap, FY2025-2026 high/low of 1,505/660, reserves of ₹7,571 Cr, and liabilities of 8,631 Cr.
What is the Market Cap of Natco Pharma Ltd?
The Market Cap of Natco Pharma Ltd is 14,798 Cr..
What is the current Stock Price of Natco Pharma Ltd as on 19 October 2025?
The current stock price of Natco Pharma Ltd as on 19 October 2025 is 826.
What is the High / Low of Natco Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Natco Pharma Ltd stocks is 1,505/660.
What is the Stock P/E of Natco Pharma Ltd?
The Stock P/E of Natco Pharma Ltd is 8.72.
What is the Book Value of Natco Pharma Ltd?
The Book Value of Natco Pharma Ltd is 425.
What is the Dividend Yield of Natco Pharma Ltd?
The Dividend Yield of Natco Pharma Ltd is 0.73 %.
What is the ROCE of Natco Pharma Ltd?
The ROCE of Natco Pharma Ltd is 32.8 %.
What is the ROE of Natco Pharma Ltd?
The ROE of Natco Pharma Ltd is 28.0 %.
What is the Face Value of Natco Pharma Ltd?
The Face Value of Natco Pharma Ltd is 2.00.